Why is cardiovascular health important in menopausal women?

被引:14
作者
Simon, T. [1 ]
机构
[1] St Antoine Univ Hosp, Dept Pharmacol, Paris, France
关键词
menopause; postmenopausal; cardiovascular disease; estrogen;
D O I
10.1080/13697130600917757
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Since endogenous estrogen shows some preventative benefits against cardiovascular risk factors in premenopausal women, cardiovascular disease (CVD) is often considered a male disease. However, CVD is the biggest cause of death in women, especially after menopause when endogenous estrogen withdrawal has detrimental effects on cardiovascular physiology and whole-body metabolism. Despite this, awareness of the risk of CVD is low in both women and in doctors; this needs rectifying. Women are underrepresented in most clinical studies of CVD. Following diagnosis of CVD, the prognosis for women is not systematically similar to that for men. Furthermore, from the few comparisons conducted, gender differences in response to pharmacological interventions are evident, so that results obtained in wholly or largely male-based studies cannot be systematically extrapolated to women. Women with CVD should be afforded equivalent investigations and treatment to men, and it is vital that women be included in clinical trials in sufficient numbers to allow sub-group analyses and subsequent development of appropriate therapies. Since CVD is usually advanced by the time symptoms appear, prevention is the key; health management advice might include smoking cessation, adoption of a healthy diet, and incorporation of physical activity into the lifestyle.
引用
收藏
页码:13 / 18
页数:6
相关论文
共 38 条
[1]  
[Anonymous], 2005, HEART DIS STROK STAT
[2]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[3]  
*COLL GROUP PRIM P, 2001, LANCET, V357, P1134
[4]   Effect of postmenopausal hormone therapy on body weight and waist and hip girths [J].
Espeland, MA ;
Stefanick, ML ;
KritzSilverstein, D ;
Fineberg, SE ;
Waclawiw, MA ;
James, MK ;
Greendale, GA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (05) :1549-1556
[5]   COMPENSATORY ENLARGEMENT OF HUMAN ATHEROSCLEROTIC CORONARY-ARTERIES [J].
GLAGOV, S ;
WEISENBERG, E ;
ZARINS, CK ;
STANKUNAVICIUS, R ;
KOLETTIS, GJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (22) :1371-1375
[6]   Guidelines on cardiovascular disease prevention in clinical practice: the European perspective [J].
Graham, IM .
CURRENT OPINION IN CARDIOLOGY, 2005, 20 (05) :430-439
[7]   Hormone therapy and coronary heart disease: The role of time since menopause and age at hormone initiation [J].
Grodstein, F ;
Manson, JE ;
Stampfer, MJ .
JOURNAL OF WOMENS HEALTH, 2006, 15 (01) :35-44
[8]   Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:: principal results of the hypertension optimal treatment (HOT) randomised trial [J].
Hansson, L ;
Zanchetti, A ;
Carruthers, SG ;
Dahlöf, B ;
Elmfeldt, D ;
Julius, S ;
Ménard, J ;
Rahn, KH ;
Wedel, H ;
Westerling, S .
LANCET, 1998, 351 (9118) :1755-1762
[9]   FINAL REPORT ON THE ASPIRIN COMPONENT OF THE ONGOING PHYSICIANS HEALTH STUDY [J].
HENNEKENS, CH .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (03) :129-135
[10]  
Hippisley-Cox J, 2001, BMJ-BRIT MED J, V322, P1